Head and Neck Squamous Cell Carcinoma (HNSCC)
52
20
27
8
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
7.7%
4 terminated out of 52 trials
66.7%
-19.8% vs benchmark
4%
2 trials in Phase 3/4
38%
3 of 8 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 8 completed trials
Clinical Trials (52)
GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors
[68Ga]Ga-FAPI-46 in Staging of Head and Neck Carcinomas
A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer
Reduction of Postoperative Radiotherapy in Head and Neck Squamous Cell Carcinoma
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
Re-radiotherapy Combined With Chidamide for the Treatment of Recurrent Head and Neck Squamous Cell Carcinoma After Radiotherapy
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer
A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors
Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC
Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers
Neoadjuvant Ficerafusp Alfa With Pembrolizumab in Resectable SCC
A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC
GV20-0251 and Sintilimab for Neoadjuvant Treatment of Resectable Head and Neck Squamous Cell Carcinoma: A Single-Arm Study
Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors
A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
A Study for Identification of Immune Determinants for Response to Nivolumab in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
Neoadjuvant Becotatug Vedotin Plus Pucotenlimab and Cisplatin for Locally Advanced Head and Neck Squamous Cell Carcinoma